Follicular Lymphoma
Conditions
Keywords
Radiotherapy, Chemotherapy, Rituximab, Randomised Trial, Stage I-II low grade follicular lymphoma
Brief summary
Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy and chemotherapy plus rituximab). The main endpoint is progression free survival but overall survival and the influence of t(14;18) status will also be studied.
Detailed description
Radiotherapy is the only modality which has been proven to have curative potential in patients with localised low grade lymphoma. Despite excellent control of the local tumour, most patients relapse outside the area treated with radiation and most of these ultimately die from lymphoma. This study tests the hypothesis that the addition of six cycles of chemotherapy plus rituximab (systemic chemotherapy) can eradicate undetectable lymphoma deposits outside the radiation field and thereby improve the cure rate. The study will specifically test the hypothesis that six cycles of adjuvant CVP chemotherapy (cyclophosphamide, vincristine, prednisolone) in combination with Rituximab will improve progression-free survival for patients with stage I and II low-grade follicular lymphoma treated with involved-field radiotherapy (IFRT). That is, will patients given radiotherapy plus systemic chemotherapy live longer or remain free from disease longer than patients treated with radiation alone? Radiotherapy alone is widely regarded as the standard treatment for this disease. There are a number of secondary endpoints to the study, as follows: 1. Comparison the pre- and post-treatment prevalence of the t(14:18) translocation, in peripheral blood and bone marrow, of patients treated with either IFRT alone or IFRT plus chemotherapy. This translocation is potentially a marker for minimal residual disease and eradication of the marker from blood cells may have prognostic implications. The clinical value of molecular remission as an early predictor of freedom from progression (FFP) and survival will be assessed. 2. Comparison of overall survival and FFP for patients treated with IFRT alone with overall survival and FFP for patients treated with combined IFRT and systemic therapy. Delay of progression of disease may be of limited value if overall survival is the same. 3. Comparison of acute and late toxicity and second malignancy rates for patients treated with IFRT or IFRT plus systemic therapy. 4. Delineation of the location of first relapse in relation to radiation therapy fields.
Interventions
DRUGCyclophosphamide
1000 mg/m2 I.V. on day 1
RADIATIONRadiotherapy
The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
DRUGVincristine
1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
DRUGPrednisolone
50 mg/m2 orally daily for days 1 - 5
DRUGRituximab
375 mg/m2 IV Infusion day 1
Sponsors
Australasian Leukaemia and Lymphoma Group
Trans Tasman Radiation Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (≥ 18 years old) with histologically documented follicular lymphoma, grade 1, grade 2, or follicular lymphoma, grade 3a diagnosed following an excisional, incisional or generous core biopsy. (i.e. an FNA alone is insufficient.) * Disease limited to stages I and II after adequate staging * Anticipated life expectancy \> 5 years * Given written informed consent * Been assessed by a radiation oncologist and a medical oncologist/ haematologist * WCC \> 3.0 x 10\^9/L, platelet count \> 100 x 10\^9/L, serum creatinine \< 0.15 mmol/L * Ability to commence radiotherapy within 6 weeks of randomisation * Women using effective contraception, are not pregnant and agree not to become pregnant during participating in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.
Exclusion criteria
* Received previous systemic cytotoxic chemotherapy. * Received previous radiotherapy, (except superficial radiation therapy for non-melanoma skin cancers). * Received previous immunotherapy. * A medical contraindication to radiotherapy, chemotherapy, or rituximab. * Any previous or concurrent malignancy other than curatively treated non-melanoma skin cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and treatment-free for 5 years. * Such extensive involvement of the thorax that treatment with radiation therapy alone would be hazardous because of excessive lung irradiation, even if a shrinking field technique were employed. * Suspected or confirmed pregnancy. Must not be lactating. * Patients who have known human immuno-deficiency virus (HIV) infection or active hepatitis B (HBV). * Treatment within a clinical study within 30 days prior to study entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS). Period from the date of randomisation to 1st progression of disease or death from any cause. | Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Main analysis will be done on completion of 5 years follow-up after the end of accrual. An interim analysis to be done after at least 3 years of follow-up. A futility analysis will be performed after the 5 year analysis. In the absence of futility being | Period from date of randomisation to date of death from any cause. |
| Location of first relapse | Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual | Period from date of randomisation to date of first relapse location via CT scan and or other imaging as required |
| Pre- and post-treatment prevalence of the t(14;18) translocation, in peripheral blood and bone marrow between arms | Peripheral blood at commencement of treatment, after 1 year and upon relapse is collected and stored for later analysis to be done as part of translational studies when funding becomes available | — |
| Freedom from progression. | Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up | Period from date of randomisation to date of first disease progression. |
| Acute and late toxicities and secondary malignances | Frame after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual | — |
| To compare time to evolution to higher histological grade | Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual | Period from date of randomisation to date of higher histological grade via CT scan and or other imaging as required |
Countries
Australia, Canada, New Zealand
Outcome results
None listed